Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Atrial Fibrillation | 90 | 2024 | 5034 | 6.540 |
Why?
|
Thiazoles | 58 | 2022 | 1483 | 6.180 |
Why?
|
Warfarin | 60 | 2024 | 1496 | 6.000 |
Why?
|
Pyridines | 60 | 2022 | 2825 | 4.560 |
Why?
|
Anticoagulants | 71 | 2024 | 4599 | 4.320 |
Why?
|
Embolism | 20 | 2023 | 408 | 3.430 |
Why?
|
Stroke | 59 | 2024 | 9981 | 2.930 |
Why?
|
Hemorrhage | 44 | 2024 | 3461 | 2.580 |
Why?
|
Thromboembolism | 11 | 2021 | 986 | 1.350 |
Why?
|
Myocardial Infarction | 24 | 2024 | 11727 | 1.240 |
Why?
|
Factor Xa | 5 | 2018 | 162 | 1.010 |
Why?
|
Acute Coronary Syndrome | 10 | 2015 | 2337 | 0.910 |
Why?
|
Cardiovascular Diseases | 15 | 2024 | 15165 | 0.910 |
Why?
|
Administration, Oral | 18 | 2024 | 3913 | 0.880 |
Why?
|
Double-Blind Method | 45 | 2021 | 12026 | 0.860 |
Why?
|
Thiophenes | 4 | 2014 | 588 | 0.750 |
Why?
|
Atherosclerosis | 5 | 2023 | 3445 | 0.740 |
Why?
|
Lipase | 1 | 2021 | 314 | 0.690 |
Why?
|
Thrombolytic Therapy | 6 | 2018 | 2161 | 0.690 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2023 | 3255 | 0.660 |
Why?
|
Anticholesteremic Agents | 3 | 2022 | 979 | 0.650 |
Why?
|
Venous Thromboembolism | 5 | 2024 | 1671 | 0.640 |
Why?
|
Coronary Artery Disease | 6 | 2023 | 6487 | 0.590 |
Why?
|
Ischemic Attack, Transient | 1 | 2023 | 935 | 0.580 |
Why?
|
Anti-Arrhythmia Agents | 3 | 2017 | 789 | 0.560 |
Why?
|
Risk Assessment | 27 | 2024 | 23338 | 0.550 |
Why?
|
Risk Factors | 45 | 2024 | 72290 | 0.540 |
Why?
|
Pyridones | 4 | 2020 | 712 | 0.540 |
Why?
|
Aged | 85 | 2024 | 163280 | 0.530 |
Why?
|
Hypoglycemic Agents | 4 | 2022 | 2872 | 0.520 |
Why?
|
Purinergic P2Y Receptor Antagonists | 3 | 2015 | 361 | 0.520 |
Why?
|
Treatment Outcome | 49 | 2024 | 63114 | 0.480 |
Why?
|
Antibodies, Antiphospholipid | 1 | 2014 | 69 | 0.480 |
Why?
|
Hemostatics | 1 | 2016 | 229 | 0.460 |
Why?
|
Humans | 143 | 2024 | 744343 | 0.460 |
Why?
|
Phosphorylcholine | 1 | 2014 | 162 | 0.460 |
Why?
|
Ticlopidine | 4 | 2014 | 899 | 0.460 |
Why?
|
Brain Ischemia | 4 | 2023 | 3265 | 0.460 |
Why?
|
Amiodarone | 1 | 2015 | 212 | 0.460 |
Why?
|
Antithrombins | 1 | 2016 | 304 | 0.460 |
Why?
|
Kidney Diseases | 2 | 2021 | 2149 | 0.420 |
Why?
|
Benzazepines | 3 | 2019 | 326 | 0.420 |
Why?
|
Middle Aged | 69 | 2023 | 213383 | 0.410 |
Why?
|
Dose-Response Relationship, Drug | 16 | 2021 | 10943 | 0.410 |
Why?
|
Natriuretic Peptide, Brain | 5 | 2023 | 1573 | 0.410 |
Why?
|
Fatty Acid-Binding Proteins | 1 | 2013 | 300 | 0.400 |
Why?
|
Drug Substitution | 1 | 2014 | 281 | 0.400 |
Why?
|
Peripheral Arterial Disease | 1 | 2022 | 1188 | 0.400 |
Why?
|
Blood Coagulation | 7 | 2021 | 1127 | 0.390 |
Why?
|
Heart Failure | 13 | 2023 | 10900 | 0.390 |
Why?
|
Thrombosis | 4 | 2024 | 2968 | 0.380 |
Why?
|
Platelet Aggregation Inhibitors | 6 | 2022 | 3068 | 0.380 |
Why?
|
Glucosides | 3 | 2019 | 451 | 0.380 |
Why?
|
Morpholines | 1 | 2014 | 571 | 0.380 |
Why?
|
Female | 86 | 2024 | 380194 | 0.370 |
Why?
|
Angina, Unstable | 4 | 2013 | 926 | 0.370 |
Why?
|
Chest Pain | 3 | 2014 | 1114 | 0.370 |
Why?
|
Pyrazoles | 4 | 2020 | 1972 | 0.360 |
Why?
|
Male | 82 | 2024 | 350118 | 0.360 |
Why?
|
Diabetes Mellitus | 4 | 2022 | 5751 | 0.360 |
Why?
|
Kidney | 3 | 2021 | 7186 | 0.360 |
Why?
|
Cholesterol, LDL | 5 | 2022 | 2356 | 0.340 |
Why?
|
Piperazines | 4 | 2016 | 2488 | 0.340 |
Why?
|
Immunoglobulin M | 1 | 2014 | 1537 | 0.340 |
Why?
|
Diabetes Mellitus, Type 2 | 7 | 2022 | 11725 | 0.330 |
Why?
|
Venous Thrombosis | 3 | 2024 | 1239 | 0.330 |
Why?
|
Benzhydryl Compounds | 3 | 2019 | 845 | 0.320 |
Why?
|
Accidental Falls | 1 | 2016 | 1062 | 0.320 |
Why?
|
Fibrinolytic Agents | 6 | 2019 | 2158 | 0.320 |
Why?
|
Appetite Depressants | 2 | 2019 | 110 | 0.320 |
Why?
|
Lipoprotein(a) | 2 | 2024 | 435 | 0.310 |
Why?
|
Peptide Fragments | 4 | 2023 | 5097 | 0.290 |
Why?
|
Aged, 80 and over | 23 | 2021 | 57776 | 0.280 |
Why?
|
Genome-Wide Association Study | 4 | 2022 | 12261 | 0.280 |
Why?
|
Troponin I | 4 | 2014 | 619 | 0.270 |
Why?
|
Atrial Function, Left | 2 | 2019 | 173 | 0.270 |
Why?
|
Randomized Controlled Trials as Topic | 11 | 2024 | 9959 | 0.270 |
Why?
|
Stroke Volume | 7 | 2023 | 5007 | 0.270 |
Why?
|
Intracranial Hemorrhages | 3 | 2021 | 855 | 0.270 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 2 | 2020 | 257 | 0.260 |
Why?
|
Enoxaparin | 1 | 2007 | 377 | 0.260 |
Why?
|
Follow-Up Studies | 15 | 2021 | 39050 | 0.250 |
Why?
|
Vitamin K | 3 | 2024 | 295 | 0.250 |
Why?
|
Proportional Hazards Models | 9 | 2021 | 12354 | 0.230 |
Why?
|
Osteoarthritis | 1 | 2011 | 1036 | 0.220 |
Why?
|
Pharmacogenetics | 5 | 2020 | 675 | 0.220 |
Why?
|
Virus Latency | 2 | 2002 | 358 | 0.220 |
Why?
|
Telemedicine | 1 | 2020 | 2872 | 0.220 |
Why?
|
Infusions, Subcutaneous | 1 | 2021 | 42 | 0.210 |
Why?
|
Gastric Inhibitory Polypeptide | 1 | 2022 | 59 | 0.210 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2011 | 2282 | 0.190 |
Why?
|
Endophenotypes | 1 | 2022 | 250 | 0.190 |
Why?
|
Prognosis | 10 | 2023 | 29063 | 0.180 |
Why?
|
Electronics | 1 | 2021 | 322 | 0.180 |
Why?
|
Retrospective Studies | 11 | 2022 | 77449 | 0.180 |
Why?
|
C-Reactive Protein | 2 | 2011 | 3778 | 0.180 |
Why?
|
International Normalized Ratio | 5 | 2020 | 367 | 0.170 |
Why?
|
Cardiac Resynchronization Therapy Devices | 2 | 2019 | 124 | 0.170 |
Why?
|
Off-Label Use | 1 | 2021 | 169 | 0.170 |
Why?
|
Serotonin 5-HT2 Receptor Agonists | 1 | 2019 | 31 | 0.170 |
Why?
|
Serine Proteinase Inhibitors | 1 | 2020 | 179 | 0.160 |
Why?
|
Critical Pathways | 1 | 2022 | 476 | 0.160 |
Why?
|
Time Factors | 13 | 2021 | 40075 | 0.160 |
Why?
|
Appetite Regulation | 1 | 2019 | 88 | 0.160 |
Why?
|
Inappropriate Prescribing | 1 | 2021 | 202 | 0.160 |
Why?
|
Cause of Death | 6 | 2019 | 3584 | 0.160 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 1 | 2022 | 293 | 0.160 |
Why?
|
Long QT Syndrome | 1 | 2022 | 453 | 0.160 |
Why?
|
Incidence | 8 | 2021 | 20947 | 0.150 |
Why?
|
Ventricular Function, Left | 3 | 2019 | 3670 | 0.150 |
Why?
|
Biomedical Technology | 1 | 2020 | 220 | 0.150 |
Why?
|
Prospective Studies | 12 | 2022 | 53288 | 0.150 |
Why?
|
Placebos | 1 | 2021 | 1676 | 0.150 |
Why?
|
Death, Sudden, Cardiac | 3 | 2016 | 1541 | 0.150 |
Why?
|
Echocardiography | 3 | 2019 | 5102 | 0.140 |
Why?
|
Digoxin | 1 | 2017 | 250 | 0.140 |
Why?
|
Obesity | 4 | 2019 | 12745 | 0.140 |
Why?
|
Hospitalization | 6 | 2022 | 10262 | 0.140 |
Why?
|
Electrocardiography | 3 | 2018 | 6442 | 0.140 |
Why?
|
Factor VIIa | 1 | 2016 | 101 | 0.130 |
Why?
|
Placebo Effect | 1 | 2019 | 502 | 0.130 |
Why?
|
Heart Atria | 2 | 2019 | 1357 | 0.130 |
Why?
|
Genotype | 6 | 2022 | 12951 | 0.130 |
Why?
|
Arthritis, Rheumatoid | 1 | 2011 | 3712 | 0.130 |
Why?
|
Primary Prevention | 1 | 2023 | 1167 | 0.130 |
Why?
|
Electric Countershock | 1 | 2018 | 534 | 0.130 |
Why?
|
Anti-Obesity Agents | 1 | 2018 | 217 | 0.130 |
Why?
|
Cholesterol, HDL | 1 | 2021 | 1814 | 0.130 |
Why?
|
Drug Utilization | 1 | 2021 | 1183 | 0.120 |
Why?
|
Longitudinal Studies | 3 | 2024 | 13989 | 0.120 |
Why?
|
Catheter Ablation | 2 | 2018 | 2758 | 0.120 |
Why?
|
Drug Discovery | 1 | 2022 | 1058 | 0.120 |
Why?
|
Blood Coagulation Factors | 1 | 2016 | 355 | 0.120 |
Why?
|
Prosthesis Implantation | 1 | 2019 | 642 | 0.120 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2002 | 1873 | 0.120 |
Why?
|
Gastrointestinal Hemorrhage | 2 | 2018 | 1130 | 0.120 |
Why?
|
Device Removal | 1 | 2019 | 656 | 0.120 |
Why?
|
CD4-Positive T-Lymphocytes | 3 | 2002 | 4386 | 0.110 |
Why?
|
Withholding Treatment | 1 | 2018 | 599 | 0.110 |
Why?
|
Pacemaker, Artificial | 1 | 2019 | 816 | 0.110 |
Why?
|
Overweight | 3 | 2019 | 2371 | 0.110 |
Why?
|
Plasma | 1 | 2016 | 575 | 0.110 |
Why?
|
Weight Loss | 3 | 2019 | 2622 | 0.110 |
Why?
|
Single-Blind Method | 1 | 2016 | 1590 | 0.110 |
Why?
|
Arginine | 1 | 2016 | 944 | 0.110 |
Why?
|
Dyslipidemias | 1 | 2020 | 849 | 0.110 |
Why?
|
Glycopeptides | 1 | 2014 | 224 | 0.110 |
Why?
|
Defibrillators, Implantable | 2 | 2019 | 1440 | 0.110 |
Why?
|
Cardiovascular Agents | 1 | 2019 | 850 | 0.110 |
Why?
|
Electrodes, Implanted | 1 | 2017 | 824 | 0.110 |
Why?
|
Bioprosthesis | 1 | 2017 | 596 | 0.110 |
Why?
|
Perioperative Care | 2 | 2018 | 1002 | 0.100 |
Why?
|
Calgranulin A | 1 | 2012 | 79 | 0.100 |
Why?
|
Calgranulin B | 1 | 2012 | 84 | 0.100 |
Why?
|
Social Class | 1 | 2021 | 1999 | 0.100 |
Why?
|
Thorax | 3 | 2019 | 547 | 0.100 |
Why?
|
Out-of-Hospital Cardiac Arrest | 1 | 2016 | 339 | 0.100 |
Why?
|
Aortic Valve Stenosis | 1 | 2024 | 1965 | 0.100 |
Why?
|
Renal Dialysis | 1 | 2021 | 1786 | 0.100 |
Why?
|
Apolipoproteins B | 2 | 2024 | 374 | 0.100 |
Why?
|
Hypoglycemia | 1 | 2018 | 861 | 0.100 |
Why?
|
Platelet Aggregation | 1 | 2014 | 798 | 0.100 |
Why?
|
Glomerular Filtration Rate | 1 | 2019 | 2170 | 0.100 |
Why?
|
Diclofenac | 1 | 2011 | 71 | 0.090 |
Why?
|
Liver Diseases | 1 | 2019 | 1253 | 0.090 |
Why?
|
Health Status Indicators | 1 | 2016 | 969 | 0.090 |
Why?
|
HIV-1 | 3 | 2002 | 6939 | 0.090 |
Why?
|
Body Weight | 4 | 2024 | 4669 | 0.090 |
Why?
|
Genetic Predisposition to Disease | 3 | 2024 | 17446 | 0.090 |
Why?
|
Cyclophosphamide | 1 | 2015 | 2242 | 0.090 |
Why?
|
Heart Valve Diseases | 1 | 2017 | 1073 | 0.080 |
Why?
|
Troponin | 1 | 2013 | 524 | 0.080 |
Why?
|
Medication Adherence | 2 | 2020 | 2063 | 0.080 |
Why?
|
Hyperlipidemias | 1 | 2013 | 789 | 0.080 |
Why?
|
Sulfones | 1 | 2011 | 437 | 0.080 |
Why?
|
Proteomics | 1 | 2021 | 3638 | 0.080 |
Why?
|
Heart Valve Prosthesis | 1 | 2017 | 1488 | 0.080 |
Why?
|
Platelet Activation | 1 | 2011 | 673 | 0.080 |
Why?
|
United States Food and Drug Administration | 1 | 2015 | 1584 | 0.080 |
Why?
|
Risk | 3 | 2019 | 9687 | 0.080 |
Why?
|
Thrombin | 1 | 2010 | 598 | 0.080 |
Why?
|
Polymorphism, Genetic | 1 | 2018 | 4328 | 0.080 |
Why?
|
Cohort Studies | 4 | 2023 | 40561 | 0.070 |
Why?
|
Comorbidity | 5 | 2020 | 10388 | 0.070 |
Why?
|
Severity of Illness Index | 3 | 2021 | 15540 | 0.070 |
Why?
|
Socioeconomic Factors | 1 | 2021 | 7785 | 0.070 |
Why?
|
Anti-HIV Agents | 1 | 2002 | 4256 | 0.070 |
Why?
|
Hypertension | 2 | 2019 | 8480 | 0.070 |
Why?
|
Registries | 2 | 2013 | 8089 | 0.070 |
Why?
|
Recombinant Proteins | 1 | 2016 | 6622 | 0.070 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2017 | 1536 | 0.070 |
Why?
|
CD40 Ligand | 1 | 2008 | 526 | 0.070 |
Why?
|
Disease Management | 1 | 2017 | 2459 | 0.070 |
Why?
|
Metabolic Clearance Rate | 2 | 2016 | 380 | 0.070 |
Why?
|
Alzheimer Disease | 3 | 2022 | 8037 | 0.070 |
Why?
|
Adult | 8 | 2023 | 214055 | 0.070 |
Why?
|
Drug Administration Schedule | 3 | 2019 | 4933 | 0.070 |
Why?
|
Databases, Factual | 1 | 2020 | 7729 | 0.070 |
Why?
|
Prevalence | 2 | 2013 | 15226 | 0.060 |
Why?
|
Peroxidase | 1 | 2008 | 611 | 0.060 |
Why?
|
Virus Replication | 2 | 2002 | 2534 | 0.060 |
Why?
|
Health Status | 1 | 2017 | 4034 | 0.060 |
Why?
|
ROC Curve | 3 | 2019 | 3527 | 0.060 |
Why?
|
Genes, pol | 1 | 2002 | 51 | 0.050 |
Why?
|
Cardiac Surgical Procedures | 1 | 2018 | 3537 | 0.050 |
Why?
|
HIV Protease | 1 | 2002 | 96 | 0.050 |
Why?
|
Dipeptidyl Peptidase 4 | 1 | 2022 | 91 | 0.050 |
Why?
|
Multicenter Studies as Topic | 2 | 2020 | 1677 | 0.050 |
Why?
|
DNA, Circular | 1 | 2002 | 97 | 0.050 |
Why?
|
Growth Differentiation Factor 15 | 1 | 2023 | 176 | 0.050 |
Why?
|
Recurrence | 4 | 2019 | 8340 | 0.050 |
Why?
|
HIV Infections | 3 | 2002 | 16718 | 0.050 |
Why?
|
HIV Reverse Transcriptase | 1 | 2002 | 213 | 0.050 |
Why?
|
Angioplasty, Balloon, Coronary | 1 | 2009 | 1873 | 0.050 |
Why?
|
Blood Platelets | 1 | 2011 | 2508 | 0.050 |
Why?
|
Subtilisins | 1 | 2020 | 83 | 0.050 |
Why?
|
Drug Monitoring | 2 | 2018 | 956 | 0.050 |
Why?
|
Emergency Medical Services | 1 | 2012 | 1917 | 0.050 |
Why?
|
Virus Integration | 1 | 2002 | 299 | 0.050 |
Why?
|
Africa | 1 | 2022 | 673 | 0.050 |
Why?
|
Heparin | 1 | 2007 | 1637 | 0.050 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2019 | 15519 | 0.050 |
Why?
|
United States | 7 | 2019 | 69872 | 0.040 |
Why?
|
Population Surveillance | 1 | 2010 | 2616 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 3 | 2017 | 6538 | 0.040 |
Why?
|
Computer Security | 1 | 2020 | 262 | 0.040 |
Why?
|
Virulence | 1 | 2022 | 1333 | 0.040 |
Why?
|
Young Adult | 2 | 2023 | 56430 | 0.040 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1999 | 494 | 0.040 |
Why?
|
Biomarkers, Pharmacological | 1 | 2019 | 162 | 0.040 |
Why?
|
Creatine Kinase, MB Form | 2 | 2009 | 214 | 0.040 |
Why?
|
Disease Progression | 3 | 2019 | 13284 | 0.040 |
Why?
|
Apolipoprotein E4 | 1 | 2022 | 668 | 0.040 |
Why?
|
Aspirin | 2 | 2020 | 3282 | 0.040 |
Why?
|
Septal Occluder Device | 1 | 2018 | 128 | 0.040 |
Why?
|
Arrhythmias, Cardiac | 1 | 2007 | 2268 | 0.040 |
Why?
|
Half-Life | 1 | 2018 | 661 | 0.040 |
Why?
|
Medication Therapy Management | 1 | 2018 | 127 | 0.040 |
Why?
|
Drug Resistance, Viral | 1 | 2002 | 820 | 0.040 |
Why?
|
Latin America | 1 | 2018 | 381 | 0.040 |
Why?
|
Neurofibrillary Tangles | 1 | 1999 | 439 | 0.040 |
Why?
|
Clinical Trials as Topic | 3 | 2020 | 7913 | 0.040 |
Why?
|
Lipoproteins | 1 | 2022 | 878 | 0.040 |
Why?
|
Digitalis Glycosides | 1 | 2016 | 47 | 0.040 |
Why?
|
Plasmids | 1 | 2002 | 2307 | 0.040 |
Why?
|
Health Services Misuse | 1 | 2018 | 243 | 0.040 |
Why?
|
Germany | 1 | 2019 | 862 | 0.040 |
Why?
|
Biological Availability | 1 | 2016 | 397 | 0.030 |
Why?
|
Europe | 1 | 2022 | 3339 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2018 | 15295 | 0.030 |
Why?
|
Diet, Reducing | 1 | 2019 | 462 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2022 | 1782 | 0.030 |
Why?
|
Lymphocytes | 1 | 2023 | 2617 | 0.030 |
Why?
|
Multifactorial Inheritance | 1 | 2022 | 1194 | 0.030 |
Why?
|
Phylogeny | 1 | 2002 | 2803 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2018 | 841 | 0.030 |
Why?
|
Survival Analysis | 2 | 2019 | 10252 | 0.030 |
Why?
|
Benzamides | 1 | 2020 | 1379 | 0.030 |
Why?
|
Aortic Valve Insufficiency | 1 | 2018 | 579 | 0.030 |
Why?
|
Kidney Function Tests | 1 | 2016 | 684 | 0.030 |
Why?
|
Body Mass Index | 2 | 2024 | 12720 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2019 | 2029 | 0.030 |
Why?
|
Sensitivity and Specificity | 3 | 2014 | 14722 | 0.030 |
Why?
|
Safety | 1 | 2018 | 1186 | 0.030 |
Why?
|
Survival Rate | 2 | 2019 | 12788 | 0.030 |
Why?
|
Thrombophilia | 1 | 2016 | 305 | 0.030 |
Why?
|
Prediabetic State | 1 | 2018 | 499 | 0.030 |
Why?
|
Cardiotonic Agents | 1 | 2016 | 535 | 0.030 |
Why?
|
Remission Induction | 1 | 2018 | 2386 | 0.030 |
Why?
|
Cholesterol | 1 | 2022 | 2917 | 0.030 |
Why?
|
Amyloid beta-Protein Precursor | 1 | 1998 | 1121 | 0.030 |
Why?
|
Molecular Sequence Data | 2 | 2002 | 18111 | 0.030 |
Why?
|
Information Dissemination | 1 | 2020 | 1099 | 0.030 |
Why?
|
Age Factors | 2 | 2022 | 18370 | 0.030 |
Why?
|
Risk Reduction Behavior | 1 | 2019 | 1125 | 0.030 |
Why?
|
Sequence Analysis, DNA | 1 | 2002 | 4803 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2022 | 2727 | 0.020 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 2016 | 859 | 0.020 |
Why?
|
Creatinine | 1 | 2016 | 1919 | 0.020 |
Why?
|
Neutrophils | 1 | 2023 | 3719 | 0.020 |
Why?
|
Pandemics | 1 | 2010 | 8388 | 0.020 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2016 | 1240 | 0.020 |
Why?
|
Internationality | 1 | 2016 | 1003 | 0.020 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2018 | 990 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2002 | 13815 | 0.020 |
Why?
|
Platelet Function Tests | 1 | 2011 | 270 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2020 | 2759 | 0.020 |
Why?
|
Infant | 2 | 2021 | 35136 | 0.020 |
Why?
|
Secondary Prevention | 1 | 2016 | 1530 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2017 | 2309 | 0.020 |
Why?
|
Critical Illness | 1 | 2022 | 2670 | 0.020 |
Why?
|
Causality | 1 | 2016 | 1275 | 0.020 |
Why?
|
Neoplasms | 1 | 2018 | 21683 | 0.020 |
Why?
|
Drug Approval | 1 | 2015 | 742 | 0.020 |
Why?
|
Neuropsychological Tests | 1 | 2022 | 6993 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2018 | 2278 | 0.020 |
Why?
|
Sex Factors | 1 | 2022 | 10397 | 0.020 |
Why?
|
Hypertension, Pulmonary | 1 | 2018 | 1537 | 0.020 |
Why?
|
Patient Discharge | 1 | 2020 | 3313 | 0.020 |
Why?
|
Pulmonary Embolism | 1 | 2020 | 2376 | 0.020 |
Why?
|
American Heart Association | 1 | 2011 | 1056 | 0.020 |
Why?
|
Mortality | 1 | 2018 | 2864 | 0.020 |
Why?
|
Homozygote | 1 | 2011 | 1785 | 0.020 |
Why?
|
Coronary Angiography | 1 | 2018 | 4577 | 0.020 |
Why?
|
Ventricular Remodeling | 1 | 2013 | 1224 | 0.020 |
Why?
|
DNA, Viral | 2 | 2002 | 2225 | 0.020 |
Why?
|
Genomics | 1 | 2021 | 5720 | 0.020 |
Why?
|
Nerve Tissue Proteins | 1 | 1998 | 4462 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2014 | 15076 | 0.020 |
Why?
|
International Cooperation | 1 | 2011 | 1420 | 0.020 |
Why?
|
Heart Rate | 1 | 2016 | 4091 | 0.020 |
Why?
|
Heterozygote | 1 | 2011 | 2804 | 0.020 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2008 | 641 | 0.020 |
Why?
|
Cognition | 1 | 2022 | 6770 | 0.020 |
Why?
|
Logistic Models | 1 | 2019 | 13408 | 0.020 |
Why?
|
Troponin T | 1 | 2009 | 754 | 0.010 |
Why?
|
Models, Theoretical | 1 | 2016 | 3589 | 0.010 |
Why?
|
Computer Simulation | 1 | 2017 | 6196 | 0.010 |
Why?
|
Pilot Projects | 1 | 2017 | 8324 | 0.010 |
Why?
|
Patient Selection | 1 | 2015 | 4215 | 0.010 |
Why?
|
Acute Disease | 1 | 2014 | 7149 | 0.010 |
Why?
|
Blood Pressure | 1 | 2019 | 8554 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2020 | 7279 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2015 | 5391 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2016 | 12245 | 0.010 |
Why?
|
HIV Long Terminal Repeat | 1 | 2002 | 88 | 0.010 |
Why?
|
HIV Integrase | 1 | 2002 | 120 | 0.010 |
Why?
|
Massachusetts | 1 | 2014 | 8663 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2018 | 21746 | 0.010 |
Why?
|
Models, Biological | 1 | 2016 | 9583 | 0.010 |
Why?
|
Child, Preschool | 1 | 2002 | 41006 | 0.010 |
Why?
|
Genetic Variation | 1 | 2015 | 6544 | 0.010 |
Why?
|
Aging | 1 | 1998 | 8664 | 0.010 |
Why?
|
Algorithms | 1 | 2020 | 13881 | 0.010 |
Why?
|
Spectrometry, Fluorescence | 1 | 1999 | 689 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2009 | 8642 | 0.010 |
Why?
|
Quality of Life | 1 | 2017 | 12804 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 2018 | 11124 | 0.010 |
Why?
|
Plaque, Amyloid | 1 | 1999 | 729 | 0.010 |
Why?
|
Tissue Distribution | 1 | 1999 | 2327 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2014 | 7659 | 0.010 |
Why?
|
Cadaver | 1 | 1998 | 1337 | 0.010 |
Why?
|
In Situ Hybridization | 1 | 1998 | 1950 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2018 | 13102 | 0.010 |
Why?
|
Enzyme Activation | 1 | 1999 | 3701 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2002 | 6171 | 0.010 |
Why?
|
Base Sequence | 1 | 2002 | 12797 | 0.010 |
Why?
|
tau Proteins | 1 | 1999 | 1868 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2002 | 7722 | 0.000 |
Why?
|
Phosphorylation | 1 | 1999 | 8436 | 0.000 |
Why?
|
Immunohistochemistry | 1 | 1998 | 11366 | 0.000 |
Why?
|
Brain | 1 | 1999 | 26385 | 0.000 |
Why?
|